ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatitis C"

  • 2017 American Transplant Congress

    Effect of Hepatitis C (HCV) Treatment on Rejection Incidence and Severity in Post-Liver Transplant Patients.

    C. Skillin, M. Mba, B. Madani, C. Frenette.

    Organ Transplant, Scripps Clinic, La Jolla, CA

    Introduction: Hepatitis C remains an important source of morbidity and mortality post liver transplant. Little is known about the long term effects of direct acting…
  • 2017 American Transplant Congress

    Use of Hepatitis C Infected Organs for Kidney Transplantation: A Medical Decision Analysis.

    B. Kiberd,1 K. Doucette,2 K. Tennankore.1

    1Dalhousie University, Halifax, NS, Canada; 2University of Alberta, Edmonton, AB, Canada

    Given that Hepatitis C (HCV) can be cured, organs from HCV+ deceased donors might be used in HCV- recipients if treatment at the time of…
  • 2017 American Transplant Congress

    HCV Eradication with DAA Therapy Should Be Attempted Prior to Liver Transplantation and Does Not Impact HCC Recurrence.

    J. Emamaullee, M. Bral, G. Meeberg, A. Montano-Loza, V. Bain, D. Bigam, N. Kneteman, A. Shapiro.

    University of Alberta, Edmonton, AB, Canada

    Background: Recent advances in the direct-acting antiviral (DAA) treatment of HCV have lead to high rates of HCV eradication, even in patients with decompensated cirrhosis.…
  • 2017 American Transplant Congress

    Occult Hepatitis C Virus in Recipients of Kidney Transplantation: Prevalence and Clinical Implications.

    C. Jimenez,1 T. Olea,1 M. Lopez,1 I. Castillo,2 J. Bartolomé,2 J. Quiroga,2 E. Gonzalez,1 V. Carreño,2 R. Selgas.1

    1Nephrology, Hospital Universitario La Paz/IdiPaz, Madrid, Spain; 2Instituto de Estudios Virales, Madrid, Spain

    Occult HCV infection (OCI) is characterized by the presence of HCV- RNA in liver or in peripheral blood mononuclear cells in the absence of serological…
  • 2017 American Transplant Congress

    Liver Allograft Hepatitis and Graft Loss After Hepatitis C Clearance.

    D. Bruno, S. Brown, S. Hanish, J. LaMattina, W. Hutson, S. Kottilil, W. Twadell, R. Barth.

    Surgery, University of Maryland School of Medicine, Baltimore, MD

    Successful HCV therapies should improve inferior outcomes of liver transplantation (LT) for HCV cirrhosis. We hypothesize certain patients may be predisposed to heterologous immunity that…
  • 2017 American Transplant Congress

    Post Transplant Outcomes in Hepatitis C Positive Patients.

    M. Lubetzky, N. Hayde, L. Kamal, M. Ajaimy, P. Bedi, G. Deboccardo, J. Rocca, S. Greenstein, J. Graham, A. Chokechanachaisakul, A. Courson, M. Kinkhabwala, E. Akalin.

    Montefiore Medical Center, Bronx

    Hepatitis C (HCV) is associated with increased morbidity and mortality after kidney transplant (KTx). We aimed to assess outcomes of HCV positive patients at our…
  • 2017 American Transplant Congress

    Transplantation of Hepatitis C Kidneys to Hepatitis C Recipients Confers Significantly Shorter Waiting Times in the Era of the New Kidney Allocation System.

    B. Concepcion, A. Langone, B. Edmundson, J. Johnson, A. Rajput, T. Johnson, D. Rybacki, D. Hale, R. Forbes.

    Nashville VA Medical Center, Nashville, TN

    Background: Prior to the new KAS, transplantation with HCV+ compared to HCV- kidneys provided shorter waiting times on the deceased donor list. In the current…
  • 2016 American Transplant Congress

    High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials.

    M. Charlton,1 E. Yoshida,2 M. Bouliere,3 S. Flamm,4 A. Muir,5 M. Fried,6 N. Terrault,7 S. Arterburn,8 C. Yun,8 P. Pang,8 A. Osinusi,8 J. Spellman,8 M. Natha,8 D. Brainard,8 J. McHutchison,8 M. Manns,9 N. Afdhal.10

    1Intermountain Medical Center, Salt Lake City; 2Vancouver General Hospital, Vancouver, Canada; 3Hopital Saint Joseph, Marseilles, France; 4Northwestern University, Chicago; 5Duke University, Durham; 6University of North Carolina, Chapel Hill; 7UCSF, SF; 8Gilead Sciences Inc, Foster City; 9Hannover Medical School, Hannover, Germany; 10BIDMC, Boston.

    Introduction: HCV infected patients with decompensated liver disease have significant morbidity & mortality. The efficacy & safety of LDV/SOF + RBV was evaluated in a…
  • 2016 American Transplant Congress

    Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant.

    J. Wiegel, T. Egbuka.

    Pharmacy, Oregon Health & Science University, Portland, OR.

    Purpose: To determine if treatment of recurrent hepatitis C virus (HCV) post-liver transplant with the direct-acting antivirals (DAAs) sofosbuvir, simeprevir, and ledipasvir (in combination and/or…
  • 2016 American Transplant Congress

    Short Duration Perioperative Administration of Ledipasvir/Sofosbuvir Is Safe and Effective in Preventing HCV Recurrence After Liver Transplant.

    E. Verna,1 J. Levitsky,2 J. O'Leary,3 N. Bzowej,4 D. Moonka,5 R. Hyland,6 D. Brainard,6 J. McHutchison,6 N. Terrault.7

    1Columbia Univ., NY; 2Northwestern Univ., Chicago; 3Baylor Univ., Dallas; 4Ochsner Clinical Foundation, New Orleans; 5Henry Ford Hospital, Detroit; 6Gilead Sciences, Foster City; 7UCSF, San Francisco.

    Background:The optimal timing and duration of DAA therapy in HCV patients undergoing liver transplant(LT) is unknown. CRUSH-C is an open-label, Phase 2 study evaluating the…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 28
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences